BioSpace News Archive

Apyx Medical Corporation today reported financial results for its fourth quarter and full year ended December 31, 2023.

Stryker (NYSE: SYK), a leading global medical technology company, announced today that it has completed the previously announced acquisition of SERF SAS, a France -based joint replacement company, from Menix.

XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock.

Theratechnologies Inc. today announced moving to the next dose level in Part 3 of its Phase 1 clinical trial of sudocetaxel zendusortide in patients with advanced ovarian cancer.

Alpine Immune Sciences, Inc. announced today that the Company presented new translational data for povetacicept (ALPN-303) at the SLEuro 14th European Lupus Meeting in Bruges, Belgium, March 19-22, 2024.

Daré Bioscience, Inc. today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, March 28, 2024, to review its financial results for the year ended December 31, 2023 and to provide a company update.

CytomX Therapeutics, Inc. today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company’s board of directors.

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) today announced that the Company will present data from its Phase 1 INTERCEPT-AD study evaluating sabirnetug (ACU193) in early AD during an Emerging Science Session at the American Academy of Neurology (AAN) Annual Meeting in Denver, Colo., and online on Tuesday, April 16.

Disc Medicine, Inc. (NASDAQ:IRON) today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided an update on recent program and corporate developments.

Renibus Therapeutics®, a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio-renal and metabolic diseases, announced a transition in its leadership structure.